Compound class:
Synthetic organic
Comment: INCB086550 is a small molecule PD-L1 inhibitor. This is the structure that was disclosed during the ACS First Disclosures session at the spring 2021 meeting. There are many potential stereo versions of this molecule, so we await formal peer-reviewed name to structure disclosure to confirm the structure. INCB086550 was designed by Incyte Corporation for activity against advanced solid tumours, as an alternative to anti-PD-L1 monoclonal antibodies. This isomer is calimed as example 24 in patent WO2018119266A1 [1].
|
|
References |
1. Wu L, Li J, Qi C, Zhang F, Li Z, Zhu W, Xiao K, Lu L, Mei S, Qian DQ et al.. (2018)
Benzooxazole derivatives as immunomodulators. Patent number: WO2018119266A1. Assignee: Incyte Corporation. Priority date: 22/12/2016. Publication date: 28/06/2018. |